[The treatment of patients with the hemorrhagic form of erysipelas by using amben and parmidine].
Amben (fibrinolysis inhibitor) and parmidin (bradykinin inhibitor) were used as pathogenetic treatment of 38 and 36 patients with hemorrhagic erysipelas respectively. Early amben treatment proved clinically rather effective and was accompanied by normalization of fibrinolysis and kallikrein-kinin system. Parmidin treatment resulted only in pain control, other subjective signs, normalization of the kallikrein-kinin system while fibrinolysis activity was maintained at former levels.
Cherkasov
V L
VL
Bol'shakova
T D
TD
Kuznetsov
V A
VA
Obrazberdyev
S
S
Mikerin
S M
SM
D010129:4-Aminobenzoic Acid / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000368:Aged; D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D004341:Drug Evaluation; D004886:Erysipelas / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006470:Hemorrhage / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011727:Pyridinolcarbamate / Q000627:therapeutic use*; D062366:para-Aminobenzoates
D000933:Antifibrinolytic Agents; D062366:para-Aminobenzoates; C015668:4-aminomethylbenzoic acid; D011727:Pyridinolcarbamate; D010129:4-Aminobenzoic Acid
Lechenie bol'nykh s gemorragicheskoĭ formoĭ rozhi ambenom i parmidinom.